Equities analysts predict that G1 Therapeutics, Inc. (NASDAQ:GTHX) will announce $370,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for G1 Therapeutics’ earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $590,000.00. The firm is expected to issue its next quarterly earnings results on Wednesday, May 5th.
On average, analysts expect that G1 Therapeutics will report full year sales of $18.60 million for the current financial year, with estimates ranging from $14.28 million to $22.40 million. For the next year, analysts forecast that the firm will report sales of $69.88 million, with estimates ranging from $59.53 million to $85.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 24th. The company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.21. The business had revenue of $16.55 million during the quarter, compared to analysts’ expectations of $14.00 million.
In other G1 Therapeutics news, insider Rajesh Malik sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 23rd. The stock was sold at an average price of $21.94, for a total value of $329,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark A. Velleca sold 10,000 shares of the business’s stock in a transaction on Thursday, February 18th. The shares were sold at an average price of $26.02, for a total value of $260,200.00. Following the completion of the transaction, the director now owns 52,040 shares of the company’s stock, valued at $1,354,080.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,040 shares of company stock worth $1,502,608. 14.49% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its holdings in shares of G1 Therapeutics by 73.8% during the 3rd quarter. State Street Corp now owns 2,365,259 shares of the company’s stock worth $27,319,000 after buying an additional 1,004,346 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of G1 Therapeutics by 82.6% during the 4th quarter. Nuveen Asset Management LLC now owns 699,335 shares of the company’s stock worth $12,580,000 after buying an additional 316,336 shares during the last quarter. BlackRock Inc. increased its holdings in shares of G1 Therapeutics by 10.0% during the 4th quarter. BlackRock Inc. now owns 2,893,593 shares of the company’s stock worth $52,056,000 after buying an additional 262,986 shares during the last quarter. Voloridge Investment Management LLC increased its holdings in shares of G1 Therapeutics by 1,237.1% during the 4th quarter. Voloridge Investment Management LLC now owns 258,777 shares of the company’s stock worth $4,655,000 after buying an additional 239,423 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its holdings in shares of G1 Therapeutics by 5,130.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 119,102 shares of the company’s stock worth $881,000 after buying an additional 116,825 shares during the last quarter. Institutional investors own 77.89% of the company’s stock.
Shares of NASDAQ:GTHX traded up $0.41 during trading on Monday, hitting $25.45. 22,013 shares of the stock were exchanged, compared to its average volume of 1,601,808. The company has a fifty day moving average price of $23.26 and a two-hundred day moving average price of $18.77. The company has a market cap of $1.07 billion, a PE ratio of -8.63 and a beta of 2.44. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.10. G1 Therapeutics has a 12-month low of $10.81 and a 12-month high of $37.07.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
Recommended Story: Gap Up Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.